This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

Clinical practice guideline on respiratory management of patients with neuromuscular weakness

patients
Credit: Pixabay/CC0 Public Domain

The American College of Chest Physicians (CHEST) recently released a new clinical guideline on respiratory management of patients with neuromuscular weakness. Published in the journal CHEST, the guideline contains 15 evidence-based recommendations, a good practice statement and an ungraded consensus-based statement.

Endorsed by the American Association for Respiratory Care, the American Thoracic Society, the American Academy of Sleep Medicine and the Canadian Thoracic Society, the include mouthpiece ventilation, transition to home , salivary secretion management and airway clearance therapies.

"Respiratory muscle weakness is a serious concern in patients with neuromuscular diseases. It can lead to inadequate ventilation, nighttime hypoventilation and the inability to mobilize secretions, which is frequently the cause of death in this population," says Akram Khan, MD, FCCP, Associate Professor, Pulmonary, Allergy and Critical Care Medicine, Oregon Health & Science University, and the lead author on the guideline. "We anticipate this guideline will standardize and improve the care provided to patients with neuromuscular diseases and subsequent weakness."

The guideline includes the following highlighted recommendations:

  • For patients with neuromuscular diseases (NMD) and chronic respiratory failure, we recommend using noninvasive ventilation (NIV) for treatment. (Strong recommendation)
  • For patients with NMD requiring NIV, we suggest individualizing NIV treatment to achieve ventilation goals. (Conditional recommendation)
  • For patients with NMD at risk for , we suggest pulmonary function testing at a minimum of every 6 months as appropriate to the course of the specific NMD. (Conditional recommendation)
  • For patients with NMD and sialorrhea, we suggest a therapeutic trial of an anticholinergic medication as firstline therapy with continued use only if there are perceived benefits compared with side effects. (Conditional recommendation)

Each recommendation is classified as strong, referred to as "recommended," or conditional, referred to as "suggested." The panel offers graded recommendations when there is sufficient evidence and ungraded consensus-based statements in areas that were thought to warrant guidance, despite an insufficient grade of evidence.

The entire list of recommendations and population, intervention, comparator and outcome questions included in the guideline can be accessed through the CHEST journal article.

More information: Akram Khan et al, Respiratory Management of Patients with Neuromuscular Weakness: An American College of Chest Physicians Clinical Practice Guideline and Expert Panel Report, Chest (2023). DOI: 10.1016/j.chest.2023.03.011

Journal information: Chest
Citation: Clinical practice guideline on respiratory management of patients with neuromuscular weakness (2023, March 14) retrieved 24 April 2024 from https://medicalxpress.com/news/2023-03-clinical-guideline-respiratory-patients-neuromuscular.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Home oxygen therapy for adults with COPD and ILD: New ATS clinical practice guideline

13 shares

Feedback to editors